Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 10/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988957 | 0.86 | LIMK1 (0.45) | CLPPLIMK1ADORA1MAP4K4 | |
| SCHEMBL4993341 | 0.84 | MEN1 (0.51) | CLPPLIMK1 | |
| SCHEMBL4986172 | 0.83 | SMN1; SMN2 (0.47) | CLPPLIMK1PDE2A | |
| SCHEMBL4986127 | 0.83 | LIMK1 (0.47) | CLPPLIMK1PDE2A | |
| SCHEMBL4988843 | 0.83 | ALDH1A1 (0.47) | CLPPLIMK1 | |
| SCHEMBL4982960 | 0.82 | LIMK1 (0.61) | LIMK1ADORA1 | |
| SCHEMBL4992354 | 0.81 | DPP4 (0.43) | CLPPLIMK1ADORA1PDE2A | |
| SCHEMBL4985989 | 0.80 | KDM4E (0.50) | CLPPLIMK1ADORA1 | |
| SCHEMBL4985030 | 0.80 | SIGMAR1 (0.50) | CLPPLIMK1 | |
| SCHEMBL4985486 | 0.79 | DRD2 (0.43) | LIMK1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CLPP 1470/4885LIMK1 1960/4885P2RX3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.